Replies to post #130074 on Avid Bioservices Inc (CDMO)

[spacey]

Several of the ongoing investigator-sponsored trials (IST) include immune correlative testing which could corroborate bavituximab's immunotherapy mechanism of action in the clinic. The company is also actively working with its clinical collaborators on how best to design future trials evaluating the potential of combining bavituximab with other immunotherapy agents

note the words Future trials. you have phase 1 then phase 2, how many years to a phase 3?

[goodJohnhunting]

The thrill is gone!

<<new immunotherapy combination studies are being planned.">>

Finally, and progression towards what Bavituximab really is, a preventative. Now, getting to this point needed to be explored, and with Dr Thorpe's blessing, but reading his patent portfolio tells me that he knew all along where Bavituximab's real success would materialize.

The problem..

microvesicles or exosomes...I've posted my concerns in the past, but to a deaf ear. Who wants to listen now? Management? Why micro vesicles? It's the environment that Bavituximab encounters that's especially problematic. Advanced stage metastatic disease, yes, a prime breeding environment for immunosuppressive exosomes of tumour origin. There's more too, but to paraphrase the issue, it's the impairment of monocyte differentiation into dendritic cells and induction of myeloid suppressive cells, that is of most concern to me.

More problems..

Someone asked about HAMA today (human anti-mouse antibodies)? The truth? A monoclonal nightmare..why? Because they are quickly eliminated from the host.

Even more problems...

Monoclonal antibodies are not effective against intracellular antigens. I just posted about this, "The relative lack of high avidity T cell receptors are a major reason why immune responses towards tumor antigens are often non-protective". Basically, if you want a vaccine, or lasting therapeutic effect there must be a target of tumor-specific antigen, or a monoclonal T-cell receptor, and Bavituximab has neither. But don't be discouraged, because all monoclonal mab's lack the fore mentioned scenario.

So what's the solution? Betabodies? Genetically engineered Bavituximab? Future combo's? How about a new general manager, with a vision for the future?

The problem is not with the PS platform! It's the lack of vision holding us back.

I'll be back in another six years when science catches up with Dr Thorpe's vision...

All the best
John
PS. Anyone hear from Mrskatie? If so I've got a question regarding Bavituximab and viral applications. Thanks..